Skip to main content
Premium Trial:

Request an Annual Quote

New York State Certifies GenetWorx to Perform Drug-Response Panel

NEW YORK (GenomeWeb) – GenetWorx said today that it has been certified by New York State to perform its drug-response genetic testing service on samples collected in the state.

The certification means Glen Allen, Va.-based GenetWorx is able to provide the test to patients in all 50 states in the US, it said. The lab is also CLIA certified.

Called the GenetWorx DNA Drug-Response Panel, the testing panel includes assays for drug metabolizing enzymes and cardiac disease risk factors. It examines a patient's genetic metabolizer type for several cytochrome 450 enzymes that activate many commonly prescribed cardiology, pain management, and psychiatry medications.

GenetWorx was founded in 2012 and provides DNA analysis for use by clinicians to support treatment decisions. In December 2013, its clinical lab received accreditation from the College of American Pathologists.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.